American Heart Association


ISC 2020: Pre-Conference Symposium III: HEADS-UP: Health Equity and Actionable Disparities in Stroke: Understanding and Problem-Solving (AM Session)

International Stroke Conference
Pre-Conference Symposia: February 18, 2020
Sessions: February 19–21, 2020

Rachel Forman, MD

I had the privilege to attend this important symposium shedding light on different aspects of stroke disparities. As someone who is passionate about stroke community education and addressing healthcare disparities, it was really incredible to be able to listen in person to people I have admired throughout my training.  The symposium was moderated by Drs. Bruce Ovbiagele and Amytis Towfighi. 

The first talk was by Dr. Mitchell Elkind (Columbia University), who began by describing disparities: “… a particular type of health difference that is closely linked with social, economic, and/or environmental disadvantage.” He also mentioned that approximately 1/3 of people in the United States, or more than 100 million people, identify as belonging to a racial or ethnic minority population. Another interesting point from the discussion is that Hispanic and Asian men and women are less likely to use EMS versus white men and women, and that black women are less likely than white women to use EMS (Journal of the American Heart Association, Smith 2015). We were then introduced to his work with the Northern Manhattan Study (NOMAS): a study of the population in Washington Heights (beginning in 1990) that has enrolled over 4,400 people from the surrounding community with neurological conditions. This work is ongoing and exciting (and, importantly, includes a diverse patient population).

ANS 2019 Sessions: “Injury to the Nervous System” and “Pathway to Success: Paving the Way for Translational Stroke Research”

The Annual Scientific Meeting of the Australasian Neuroscience Society
December 2–5, 2019

Lin Kooi Ong, PhD

Rebecca Hood, PhD*

The Annual Scientific Meeting of the Australasian Neuroscience Society was held December 2 to 5 in Adelaide. There were many high-quality and exciting sessions. We would like to highlight two key sessions that focused on stroke and brain injury.

The first session, “Injury to the Nervous System,” provided the audience a sample of the insights gleaned from various studies on injury to the nervous system. Dr. Shenpeng Zhang (La Trobe University) kicked off the session with a retrospective analysis of 5 years’ experimental stroke data from 716 mice to identify interrelationships between measures such as infarct volume, brain edema, functional outcomes and leukocytes.

Interview: Dr. Noortje Maaijwee, MD, PhD, on Highlights from ESOC 2019

Dr. Noortje Maaijwee
Dr. Noortje Maaijwee

An interview with Dr. Noortje Maaijwee, MD, PhD, a neurologist specializing in neurorehabilitation. She is a full-time faculty member in the Department of Neurology and Neurorehabilitation at the Lucerne Cantonal Hospital in Switzerland. She completed her medical school and residency at Radboud University Nijmegen Medical Centre in the Netherlands. Her primary area of research interest includes stroke in young adults, long-term consequences of stoke, and quality of life issues after suffering a stroke. During her PhD, Dr. Maaijwee defended a thesis on “Long-term neuropsychological and social consequences after stroke in young adults.”

Interviewed by Dr. Rohan Arora, MD, Assistant Professor of Neurology, director of stroke fellowship at the Hofstra Northwell School of Medicine and medical director of the stroke program at LIJ Forest Hills, a part of Northwell Health, New York.

In this interview, Dr. Maaijwee discusses highlights from the European Stroke Organization Conference, held May 22–24 in Milan, Italy.

Dr. Arora: At ESOC 2019, what were some major breakthroughs? 

Dr. Maaijwee: The indications and contra-indications for acute treatment of ischemic stroke by IV thrombolysis and endovascular therapy are ever-changing. For example, the time-window when treatment is successful. In the Large Clinical Trials session on the first day of ESOC, a meta-analysis was presented that showed that intravenous thrombolysis increases the percentage of good clinical outcome (modified Rankin Score (mRS) 0-1) at 3 months, if treatment is started between 4.5–9 hours after onset of symptoms in select patients with CT or MRI perfusion mismatch.1

ESOC 2019 Session: Intracerebral Haemorrhage I

European Stroke Organisation Conference
May 22–24, 2019

Andrea Morotti, MD

This interesting session dedicated to intracerebral hemorrhage (ICH) started with a pragmatic talk on rare causes of intracranial bleeding, discussing the diagnostic accuracy of neuroimaging in the acute phase, by Floris Schreuder.

Christian Weimar presented the main strengths and limitations of currently available tools to stratify ICH prognosis.

The pathophysiology and management of perihematomal edema was illustrated by Kevin Sheth, with a focus on edema measurement with advanced neuroimaging.

ESOC 2019 Session: Endovascular Treatment – Clinical Practice

European Stroke Organisation Conference
May 22–24, 2019

Elena Zapata-Arriaza, MD

The annual European Stroke Organisation Conference was held May 22 to 24 in Milan. There were countless sessions with a high scientific quality. In particular, the scientific communications session “Endovascular Treatment – Clinical Practice,” held on May 22, revealed interesting findings. Among all the refreshing results, I would like to highlight the following:

Dr. Georgios Tsivgoulis, from the National & Kapodistrian University of Athens, showed interesting data about a systematic review and meta-analysis of bridging therapy (BT) versus direct mechanical thrombectomy(MT) in stroke patients with large vessel occlusion (LVO). The mentioned systematic review included 38 studies with a sample of 11.798 patients. The main conclusions of the study exposed that pretreatment with IVT does not increase complication nor results in measurably delayed reperfusion in LVO patients treated with MT. In addition, their results, also showed a potential benefit on functional outcome and mortality in patients receiving BT compared to direct MT.

ESOC 2019: Insights from the Large Clinical Trials Sessions, May 23 and 24

European Stroke Organisation Conference
May 22–24, 2019

Aristeidis H. Katsanos, MD, PhD

Thursday, May 23

In the first presentation of the second day of the Large Clinical Trials section, Dr. Hatem Wafa presented a study on the burden of stroke in Europe: 30-year projections of incidence, prevalence, deaths and disability-adjusted life years (DALYs). Dr. Wafa presented data on the epidemiological trends and demographic changes in stroke epidemiology across Europe, using data from the global burden of disease (GBD) between 1990 and 2017. Future trajectories up to 2047 were based on population projections and GDP prospects. Investigators found that the absolute burden of stroke increased between the years 1990 and 2017 and will continue to increase through 2047 in most EU countries. Lithuania was found to be the country with the largest increase in both stroke incidence (+0.48%) and prevalence (+0.7%), while Portugal was found to have the greatest reductions in both metrics (-1.57% and -1.3%, respectively). Stroke survivors are expected to increase by 27%, posing the need for more rehabilitation services and care homes.

In the presentation of a post-hoc analysis from the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) trial on the interaction of blood pressure (BP) lowering and alteplase dose in thrombolysis-eligible acute ischemic stroke (AIS) patients, it was reported that in thrombolysis-treated AIS patients, low (0.6 mg/kg) vs. standard-dose alteplase (0.9 mg/kg) does not clearly modify the treatment effects of intensive (systolic BP<130-140mmHg) vs. guideline BP lowering (SBP<180mmHg) on the primary outcome of functional outcome, intracranial hemorrhage (ICH), death or serious adverse events. Investigators concluded that intensive BP lowering does not improve functional recovery or ICH risk with either low or standard-dose alteplase.

ESOC 2019 Session: Cerebral Small Vessel Disease

European Stroke Organisation Conference
May 22–24, 2019

Raffaele Ornello, MD

At the 5th European Stroke Organisation Conference, there was an interesting session on Thursday, May 23, about small vessel disease (SVD), a frequent cause of ischemic and hemorrhagic stroke.

Professor Leif Østergaard from Aarhus University presented the role of the alterations of capillary hemodynamics in the pathogenesis of SVD, while Professor Nikolaus Plesnila from the University of Munich discussed the role of pericytes in brain ischemia and neurodegeneration.

ESOC 2019 Session: Future Directions on Thrombolysis

European Stroke Organisation Conference
May 22–24, 2019

Lina Palaiodimou, MD

In general, this year’s European Stroke Organisation Conference was characterized by the presentation of numerous clinical dilemmas and highlighted the need for new research targeted to their resolution, which is most likely to be found on the ground of personalized medicine. The session “Future Directions on Thrombolysis” provided some insight about subjects regarding management of acute ischemic stroke that have perpetually troubled clinicians during everyday practice.

The first talk, by William Whiteley, confirmed safety and efficacy of intravenous thrombolysis using data from the analysis of pooled stroke thrombolysis trials. Specifically, it was confirmed that the proportional benefits of alteplase increase with earlier treatment, and this association is independent of age and stroke severity. There is, of course, an increased risk of death from intracerebral hemorrhage (ICH) in the alteplase treated patients, but there is no significant effect on other causes of early or later death. Among those patients treated earlier, there is a suggestion that the early hazard due to death from ICH may be compensated by a later benefit regarding death from any cause within 90 days. Whiteley finally concluded, presenting a well-intelligible graph, that the absolute balance of benefit versus risk depends chiefly on treatment delay and stroke severity.   

ESOC 2019 Session: Official Welcome & Large Clinical Trials

European Stroke Organisation Conference
May 22–24, 2019

Alan C. Cameron, MB ChB, BSc (Hons), MRCP

The 5th European Stroke Organisation Conference (ESOC 2019) has opened with a fantastic session in Milan on Wednesday! The conference was opened by ESO President Bart van der Worp, Conference Chair Jesse Dawson, and Chair of the Local Organising Committee Danilo Toni, who welcomed over 5,500 participants from 94 countries to the conference, which has doubled in size since inception over the last four years.

Ten landmark studies were presented at the official welcome. Key highlights include results from RESTART, which answers whether to start or avoid antiplatelet therapy after ICH in patients taking antiplatelets for the prevention of occlusive vascular disease. Remarkably, restarting antiplatelet therapy does not increase major haemorrhagic events. In contrast, restarting antiplatelet therapy may reduce recurrent ICH and protect against recurrent major vascular events. This provides reassuring evidence on restarting antiplatelet medication for secondary prevention of occlusive vascular disease in patients with ICH.

RESILIENT demonstrates the overwhelming efficacy of mechanical thrombectomy persists when implemented in the challenges of a developing country healthcare system such as Brazil. In this setting, thrombectomy decreases disability with a number needed to treat of only 6.6, has low complication rates and no increase in symptomatic ICH compared to medical therapy. We must now ensure the tremendous benefits of thrombectomy are available to more patients globally, including developing countries. 

ISC 2019: Acute Endovascular Treatment Oral Abstracts III

International Stroke Conference
February 6–8, 2019

Deepak Gulati, MD

There is uncertainty about factors affecting collaterals, natural course of collaterals and the type of anesthesia during thrombectomy. The session started with the detailed analysis of the GOLIATH trial to identify predictors of collateral circulation grade, infarct growth at 24hrs and the effect of collaterals on clinical outcome. The GOLIATH trial was a single center RCT comparing GA vs CS in acute patients with ELVO within 6 hours. Successful reperfusion was better in GA vs CS (76.9% vs 60.3, p=0.04). This study categorized Grade 2 ASTIN Collateral grading into 2- and 2+ based on <50% or >50% defect in ischemic territory, respectively. The anesthesia protocol included MAP>70 but could not be achieved in 26% of the entire population (35.4% in GA vs 15.9% in CS). Patient were also found to be hypocarbic with median ET CO2 of 33mmHg. There is no effect of collaterals noticed on clinical outcomes. Infarct growth is found to be associated with the use of pressor use (phenylephrine). This study concluded that sedation induced intraprocedural BP drop has a deleterious effect on collateral circulation and may not be reversed by IV pressor administration.